Michael Kauffman
CIK 1364719 · President of Development · last filed 2026-05-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$15.50M
Companies
10
Total Filings
114
Lifetime Open-Market Net
-$20.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | -$82.2K | 11 | 2026-05-11 |
| VSTM | President of Development | 8,666 | $4.10 | $35.5K | -$51.8K | 19 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | — | $9.75 | — | $0 | 1 | 2025-06-06 |
| NCNA | Director | — | $1.95 | — | $0 | 1 | 2024-08-23 |
| ACET | Director | 11,800 | $8.05 | $95.0K | -$8.4K | 5 | 2024-06-07 |
| KPTI | Chief Executive Officer | 1,618,114 | $9.50 | $15.37M | -$19.88M | 64 | 2022-03-02 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-06-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chief Medical Officer | 9,000 | — | — | $0 | 2 | 2010-02-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 3 | 2010-01-20 |
| BIOENVISION INC (BIVN) Delisted | Director | — | — | — | $0 | 1 | 2007-01-05 |
Recent Filings · Page 3 of 12
114 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-03-02 | KPTI | Mixed | +8,548 | -$127.5K | EDGAR |
| 2022-02-22 | KPTI | Sell (S) | −18,167 | -$220.2K | EDGAR |
| 2022-02-09 | KPTI | Sell (S) | −13,471 | -$132.9K | EDGAR |
| 2022-01-05 | Kezar Life Sciences, Inc. (KZR) Delisted | Mixed | — | -$52.7K | EDGAR |
| 2021-11-18 | ACET | Grant (A) | — | $0 | EDGAR |
| 2021-06-30 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-30 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2021-03-23 | KPTI | Sell (S) | −4,000 | -$49.6K | EDGAR |
| 2021-03-01 | KPTI | Grant (A) | +114,400 | $0 | EDGAR |
| 2021-02-22 | KPTI | Sell (S) | −18,990 | -$281.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.